These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20479099)

  • 21. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
    Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
    Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.
    Clin Prostate Cancer; 2005 Sep; 4(2):83-5. PubMed ID: 16197607
    [No Abstract]   [Full Text] [Related]  

  • 24. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia.
    Andersen CL; McMullin MF; Ejerblad E; Zweegman S; Harrison C; Fernandes S; Bareford D; Knapper S; Samuelsson J; Löfvenberg E; Linder O; Andreasson B; Ahlstrand E; Jensen MK; Bjerrum OW; Vestergaard H; Larsen H; Klausen TW; Mourits-Andersen T; Hasselbalch HC
    Br J Haematol; 2013 Aug; 162(4):498-508. PubMed ID: 23758082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors and colorectal cancer: what is new?
    Tampakis A; Tampaki EC; Nebiker CA; Kouraklis G
    Anticancer Agents Med Chem; 2014; 14(9):1220-7. PubMed ID: 25246306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
    Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
    J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bring back the acetyls - a novel anticancer movement.
    Melton L
    Lancet Oncol; 2003 Dec; 4(12):710. PubMed ID: 14682340
    [No Abstract]   [Full Text] [Related]  

  • 29. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
    Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy.
    Witt O; Lindemann R
    Cancer Lett; 2009 Aug; 280(2):123-4. PubMed ID: 19303208
    [No Abstract]   [Full Text] [Related]  

  • 31. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.
    de Marinis F; Atmaca A; Tiseo M; Giuffreda L; Rossi A; Gebbia V; D'Antonio C; Dal Zotto L; Al-Batran SE; Marsoni S; Wolf M
    J Thorac Oncol; 2013 Aug; 8(8):1091-4. PubMed ID: 23857399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
    Puvvada SD; Li H; Rimsza LM; Bernstein SH; Fisher RI; LeBlanc M; Schmelz M; Glinsmann-Gibson B; Miller TP; Maddox AM; Friedberg JW; Smith SM; Persky DO
    Leuk Lymphoma; 2016 Oct; 57(10):2359-69. PubMed ID: 26758422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.
    Hofmeister CC; Williams N; Geyer S; Hade EM; Bowers MA; Earl CT; Vaughn J; Bingman A; Humphries K; Lozanski G; Baiocchi RA; Jaglowski SM; Blum K; Porcu P; Flynn J; Penza S; Benson DM; Andritsos LA; Devine SM
    Leuk Lymphoma; 2015 Apr; 56(4):1043-9. PubMed ID: 25213183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitors: novel agents in cancer treatment.
    Glass E; Viale PH
    Clin J Oncol Nurs; 2013 Feb; 17(1):34-40. PubMed ID: 23372094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
    Richon VM
    Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Campbell P; Thomas CM
    J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.
    Cassier PA; Floquet A; Penel N; Derbel O; Bui N'guyen B; Guastalla JP; Pissaloux D; Treilleux I; Saba CE; Blay JY; Ray-Coquard I
    Ann Oncol; 2014 May; 25(5):1074-5. PubMed ID: 24651409
    [No Abstract]   [Full Text] [Related]  

  • 39. [Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].
    Stegmann DA
    Med Monatsschr Pharm; 2016 Apr; 39(4):142-7. PubMed ID: 27209894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Panobinostat (Farydak) for multiple myeloma.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):e118-9. PubMed ID: 26262884
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.